ISG Forms Partnership with Re:infer to Help Enterprises Derive Value from Conversational Data

ISG Forms Partnership with Re:infer to Help Enterprises Derive Value from Conversational Data

Powered by AI, clients can analyze conversations to improve collaboration, efficiency, agility and customer service

STAMFORD, Conn.–(BUSINESS WIRE)–
ISG Automation, the pure-play intelligent automation business of Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm, said today it is partnering with Re:infer, a London-based provider of an AI platform solution that helps clients derive business value from analyzing both external and internal conversations.

Re:infer, founded in 2015 by Ph.D. scientists from the AI research lab at University College London, uses machine learning technology to understand the massive amounts of communications data generated by the typical business each day—data previously lost or ignored due to processing limitations. The Re:infer conversational data intelligence platform helps organizations gain insights from every conversation, bringing teams together and the business closer to its customers.

“Communications mining—that is, analyzing unstructured, text-based messages for insights—is the next frontier in digital transformation,” said Wayne Butterfield, director, ISG Automation. “Our partnership with Re:infer will give our clients a new understanding of what their employees, customers and other constituents are saying, and how to use that insight to make the business more efficient, more agile and more attuned to customer needs and market opportunities.”

Re:infer’s deep learning technology automates the interpretation of conversational data and bridges the gap between humans and information technology systems, and between unstructured and structured data, said Ed Challis, co-founder and CEO of Re:infer.

“Re:infer gives our clients’ infrastructure a new perceptual capability to listen and understand any of their communications in real time and at scale,” Challis said. “Clients can detect and service customer needs they’d otherwise miss—accounting for huge increases in customer satisfaction. By automating conversational data, we drastically improve fulfillment from hours to seconds and massively increase throughput and efficiency—in some settings by over a thousand times.”

The Re:infer conversational data intelligence platform allows users to deploy custom machine-learning models to analyze their communications data, converting each message into structured, machine-readable data in real time. The zero-code platform allows business users to create their own AI models, for greater specificity and flexibility. The platform’s self-learning capability continuously improves model accuracy.

“ISG Automation continues to add value to its portfolio of automation solutions by bringing the best cognitive capabilities to our clients,” said Chip Wagner, CEO of ISG Automation. “Our partnership with Re:infer meets an important need for clients who are looking to automate the interpretation of their unstructured data to inform their automated business processes. Working with Re:infer, our clients will be able to optimize their revenue potential by deriving new insights from customer conversations, while optimizing cost, efficiency and scalability across the enterprise.”

ISG Automation’s alliance with Re:infer is in line with its strategy of partnering with the world’s leading automation software and service providers to bring the benefits of intelligent process automation to clients. ISG Automation clients will have immediate access to the Re:infer platform and ISG Automation will be able to introduce its full range of services to Re:infer clients.

ISG Automation is the pure-play intelligent automation unit of ISG with a full portfolio of services, including automation assessments and strategy, proof-of-concept deployments, implementation and integration of software bots, establishment of centers of excellence to scale automation, as well as training and managed services. For more about ISG Automation, visit this webpage.

About Re:infer

Re:infer is a conversational data intelligence platform built for the enterprise that unlocks the value contained in conversational data for every team in the business to better understand the customer and serve them more efficiently. It allows users to turn any message into structured, actionable data, and build intelligent products, services and workflows to drive scalability and improve the customer experience. For more information, visit reinfer.io.

About ISG

ISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 700 clients, including more than 75 of the world’s top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,300 digital-ready professionals operating in more than 20 countries—a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry’s most comprehensive marketplace data. For more information, visit www.isg-one.com.

Will Thoretz, ISG

+1 203 517 3119

[email protected]

Cait Buckley, Matter Communications for ISG

+1 617 874 5214

[email protected]

KEYWORDS: Connecticut Europe United States United Kingdom North America

INDUSTRY KEYWORDS: Electronic Design Automation Professional Services Data Management Technology Software Consulting Internet

MEDIA:

Logo
Logo

Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA for Psychedelic Drug DMT Clinical Research Program for Stroke

VANCOUVER, British Columbia, May 17, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) announces it has received positive feedback from the U.S. Food and Drug Administration (FDA) regarding its plans to investigate AP-188 (“N,N-Dimethyltryptamine” or “DMT”), a known psychedelic compound that is part of the tryptamine family, as an adjunct to physical therapy in the rehabilitation of stroke.

In a Pre-IND request submitted March 16, 2021, Algernon sought direction from the FDA regarding the design and scope of the Company’s preclinical and early phase stroke clinical programs. The FDA is in agreement with the Company’s planned preclinical efficacy experiments and offered guidance with regards to supportive preclinical safety studies. In addition, the FDA provided valuable input into the design of the Company’s planned Phase 1 clinical trial, which will be conducted through Hammersmith Medicines Research in the UK, in Q4 2021.

“On February 1, 2021, Algernon announced that it was planning to be the first Company in the world to test DMT in human clinical trials for stroke, and that is an objective we are aggressively pursuing,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals. ”While we will begin with investigating DMT as an adjunct to physical therapy in the rehabilitation of stroke patients, we are currently engaged in preclinical research that will inform us on our planned Phase 2 for ischemic stroke as well. Algernon will file an additional Pre-IND meeting request with the FDA for its planned ischemic stroke program when its preclinical research program is complete.”

Algernon has filed new provisional patents for new forms of DMT, in addition to formulation, dosage and method of use claims for ischemic stroke. The Company has also filed claims for combination therapy of DMT and Constraint Induced Movement Therapy.

About Algernon Pharmaceuticals Inc. 

Algernon is a drug re-purposing company that investigates well-tolerated, already approved drugs, including naturally occurring compounds for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

CONTACT INFORMATION

Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701

[email protected] 
[email protected] 
www.algernonpharmaceuticals.com

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.



Foghorn Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Program of FHD-286


– First clinical candidate of a new class of therapeutics directly targeting the chromatin regulatory system


– FHD-286 is a highly potent, selective, allosteric, oral, small molecule inhibitor of BRG1/BRM

CAMBRIDGE, Mass., May 17, 2021 (GLOBE NEWSWIRE) — Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that the first patient has been dosed in a first-in-human clinical trial of FHD-286 in metastatic uveal melanoma (mUM). A separate clinical study of FHD-286 in relapsed/refractory acute myelogenous leukemia (AML) is also underway.

FHD-286 is a selective inhibitor of the BAF chromatin remodeling complex ATPases BRG1 and BRM, and the first program in Foghorn’s diverse pipeline of novel drug candidates targeting genetically determined dependencies within the chromatin regulatory system. FHD-286 is not only the company’s first clinical stage program, the company believes it is also the first drug candidate directly targeting the chromatin regulatory system to enter clinical trials.

“Initiating our first clinical studies of FHD-286 is an important milestone for Foghorn, validating the potential of our Gene Traffic Control® platform to develop novel therapeutics and improve the lives of people with devastating diseases,” said Sam Agresta M.D., M.P.H., Chief Medical Officer of Foghorn Therapeutics. “People with metastatic uveal melanoma and relapsed/refractory AML as well as MDS have limited treatment options. Based on our precise understanding of the dependencies that these cancers have on the chromatin regulatory system, we believe our dual inhibitor, FHD-286, has the potential to alter the course of disease of these people with uveal melanoma and AML as well as other diseases. In addition, we are continuing to study the effects of BRG1/BRM inhibition in other solid and hematologic tumor types for potential indication expansion in the future.”

Both the FHD-286 metastatic uveal melanoma and AML (including MDS), clinical trials are first-in-human and first-in-class. Each is an open-label, monotherapy, dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics and clinical activity of FHD-286 administered orally. To learn more about the first-in-human clinical trial of FHD-286 in metastatic uveal melanoma, please visit here.

About FHD-286

FHD-286 is a highly potent, selective, allosteric and orally available, small-molecule, enzymatic inhibitor of BRG1 and BRM, two highly similar proteins that are the ATPases, or the catalytic engines across all forms of the BAF complex, one of the key regulators of the chromatin regulatory system. In preclinical studies, FHD-286 has shown anti-tumor activity across a broad range of malignancies including both hematologic and solid tumors.

About AML

Adult acute myeloid leukemia (AML) is a cancer of the blood and bone marrow and the most common type of acute leukemia in adults. AML is a diverse disease associated with multiple genetic mutations. It is diagnosed in about 20,000 people every year in the United States.

About Uveal Melanoma

Uveal (intraocular) melanoma is a rare eye cancer that forms from cells that make melanin in the iris, ciliary body, and choroid. It is the most common eye cancer in adults. It is diagnosed in about 2,000 adults every year in the United States and occurs most often in lightly pigmented individuals with a median age of 55 years. However, it can occur in all races and at any age. UM metastasizes in approximately 50% of cases, leading to very poor prognosis.

About Foghorn Therapeutics

Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.

Forward-Looking Statements

This press release contains “forward-looking statements” regarding the Company’s clinical programs for FHD-286. Forward-looking statements include statements regarding the Company’s clinical trial, product candidates and research efforts and other statements identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risk regarding the timing of filing an IND for our product candidates and other factors set forth under the heading “Risk Factors” in the Company’s Form 10-K. Any forward-looking statement made in this press release speaks only as of the date on which it is made.

Media Contact:

Fanny Cavalié, Foghorn Therapeutics
[email protected]

Gregory Kelley, Ogilvy
[email protected]

Investor Relations Contact:

Allan Reine, Foghorn Therapeutics
[email protected]

Hans Vitzthum, LifeSci Advisors
617-430-7578
[email protected]



Vine Energy Inc. Announces First-Quarter 2021 Results and Provides 2021 Guidance

Vine Energy Inc. Announces First-Quarter 2021 Results and Provides 2021 Guidance

PLANO, Texas–(BUSINESS WIRE)–
Vine Energy Inc. (NYSE: VEI) (“Vine” or the “Company”) today reported first-quarter 2021 results and provided full-year 2021 guidance and select guidance for the second-quarter 2021.

Highlights

  • Completed IPO on March 17, 2021, raising net proceeds of approximately $322 million
  • Issued $950 million of 8-year, 6.75% senior unsecured notes to retire predecessor company notes; projected to save nearly $20 million per year in cash interest expense
  • Closed on a new reserves-based lending facility (“RBL”) with an initial borrowing base of $350 million

The highlights presented below reflect select financial metrics from the unaudited financial statements for the three months ended March 31, 2021 and 2020, and include the results of the predecessor Vine Oil & Gas LP for the entire period and the results of Brix Oil & Gas Holdings LP and Harvest Royalties Holdings LP from March 17, 2021, the effective date of the combination resulting from the corporate reorganization in connection with the initial public offering.

First-Quarter 2021 Select Financial Highlights

 

 

Q1 2021

 

Q1 2020

 

Change

($ millions, except per share metrics)

 

 

 

 

 

 

Production (MMcfd)

 

 

 

724

 

 

 

622

 

 

 

102

Revenue, w/derivatives

 

$

 

118

 

$

 

130

 

$

 

(12

)

Operating Income

 

$

 

(23

)  

$

 

3

 

$

 

(26

)

Operating Cash Flow

 

$

 

105

 

$

 

100

 

$

 

5

Net Income

 

$

 

(58

)  

$

 

(27

)  

$

 

(31

)

Net Income attributable to Vine

 

$

 

(16

)  

 

 

 

Earnings per share

 

$

 

(3.95

)  

 

 

 

The unaudited financial statements are presented in their entirety in the appendix of this release.

To facilitate a clearer representation of first-quarter 2021 performance, all results presented hereinafter are pro forma for the combination resulting from the corporate reorganization and initial public offering as if the transactions occurred on January 1, 2020.

Financial and Operational Highlights

  • Generated $145 million of adjusted EBITDAX and $20 million of Adjusted Free Cash Flow
  • Incurred capital of $98 million, or 68% of adjusted EBITDAX
  • Announced 2021 capital guidance, which is projected to yield average annual production of approximately 1 Bcf per day (net) while generating substantial Adjusted Free Cash Flow
  • Continued to demonstrate progress toward the Company’s objective to reduce methane and greenhouse gas intensity

Reflecting on the quarter, Eric Marsh, Chairman, President and Chief Executive Officer, commented, “Our initial public offering begins a sequel in Vine’s short but exciting history, and it was undoubtedly the most transformational quarter since 2014 when the company was created by the acquisition of our Haynesville asset. Following the combination of three successful companies, Vine today holds a strategic position in the Haynesville Basin and we have the size, scale and balance sheet to generate significant levered free cash flow and return capital to our shareholders, while concurrently upholding our longstanding commitment to safety and environmental stewardship.”

Mr. Marsh continued, “Though there are many new things about us, our core identity hasn’t changed. Most notably, we have about 25 years of high-quality inventory that supports our ability to create free cash flow longevity, and our operating team is one of the most highly skilled, technical collection of professionals in the industry. We harbor the institutional knowledge and technology which allows us to drill some of the most economic natural gas wells in North America. We believe we can eclipse past milestones as we reach new drilling and completion efficiencies, drive down capital intensity and operating expenses, and deliver on our expectations. Along the way, I believe improving natural gas fundamentals will hasten our bid to substantially increase the value of the company while holding production steady.”

First-Quarter 2021 Select Financial Highlights (Pro Forma)

 

 

Q1 2021 

 

Q1 2020

 

Change 

($ millions, except for per unit metrics)

 

 

 

 

 

 

Production (MMcfd)

 

 

945

 

 

859

 

 

86

 

Average Realized Price, w/realized derivatives ($/Mcf)

 

$

2.34

 

$

2.39

 

$

(0.05

)

Operating Expenses ($/Mcf)

 

$

0.63

 

$

0.66

 

$

(0.03

)

Adjusted EBITDAX

 

$

145

 

$

136

 

$

9

 

Capital Incurred

 

$

98

 

$

99

 

$

(1

)

Adjusted Free Cash Flow

 

$

20

 

$

12

 

$

8

 

Production increased 86 MMcfd compared to the prior year quarter due to new wells brought online, improved operational efficiencies and exceptional PDP performance. However, production was negatively impacted by 28 MMcfd averaged over the first quarter due to winter storm Uri in February 2021 that forced temporary well curtailments.

Average realized price, including realized gain/loss on derivatives, was $2.34 per Mcf, $0.05 per Mcf lower compared to the prior year quarter, as follows:

 

 

Q1 2021 

 

Q1 2020

 

Change 

NYMEX settlement price (MMBtu) (1)

 

$

2.69

 

 

$

1.95

 

 

$

0.74

 

Basis differential, including firm sales

 

 

(0.13

)

 

 

(0.18

)

 

 

0.05

 

Fuel component of gathering

 

 

(0.07

)

 

 

(0.05

)

 

 

(0.02

)

BTU factor

 

 

(0.09

)

 

 

(0.07

)

 

 

(0.02

)

Prior-period adjustments and non-operated sales

 

 

(0.04

)

 

 

(0.01

)

 

 

(0.03

)

Average realized price, excluding derivatives (Mcf)

 

$

2.36

 

 

$

1.64

 

 

$

0.72

 

Realized gain/(loss) on derivatives

 

 

(0.02

)

 

 

0.75

 

 

 

(0.77

)

Average realized price, including derivatives (Mcf)

 

$

2.34

 

 

$

2.39

 

 

($

0.05

)

(1)

 

Based on posted futures settlement

Total operating expense, excluding DD&A, strategic and exploration expense, and the non-cash gain on the gathering liability, decreased $0.03 per Mcf compared to the prior year quarter. Lease operating expense was impacted by costs related to winter storm Uri and higher produced water volume, while cash gathering expense benefited from a step down in the contractual rate in September 2020. G&A expense was lower by $0.02 due to the June 2020 reduction in force and operating leverage on higher production volume.

per Mcf

 

Q1 2021

 

Q1 2020

 

Change 

Lease operating

 

$

0.22

 

$

0.20

 

$

0.02

 

Gathering & treating, excluding non-cash gain

 

 

0.31

 

 

0.32

 

 

(0.01

)

Prod & ad-valorem taxes

 

 

0.06

 

 

0.06

 

 

0.00

 

General & administrative

 

 

0.05

 

 

0.07

 

 

(0.02

)

Total (may not foot due to rounding)

 

$

0.63

 

$

0.66

 

$

(0.03

)

Adjusted EBITDAX in the first-quarter 2021 was $145 million compared to $136 million in the prior year quarter, or approximately 73% of revenue, excluding unrealized derivative losses, in both periods. The increase was largely due to higher production volume, partially offset by lower average realized prices. With the sum of capital incurred and cash interest essentially flat year-over-year, Adjusted Free Cash Flow was $20 million compared to $12 million in the prior year quarter.

Refer to “Non-GAAP Financial Measures” in the appendix of this release for a definition of Adjusted EBITDAX and Adjusted Free Cash Flow and related disclaimers.

Operating Results

Development and completion capital incurred in the first-quarter 2021 was $92 million to drill 7 gross (6.2 net) wells and complete 11 gross (10.4) net wells, while other field capital was $6 million related to the buildout of the Company’s water gathering and disposal infrastructure, midstream, leasing and other miscellaneous investments.

Q1 2021

 

Haynesville

 

Mid-Bossier

 

Total

 

 

Gross

 

Net 

 

Gross

 

Net 

 

Gross 

 

Net 

Wells Drilled

 

3

 

2.9

 

4

 

3.3

 

7

 

6.2

Wells Turned-In-Line (TIL)

 

9

 

8.4

 

2

 

2.0

 

11

 

10.4

Completed Lateral (ft)

 

 

 

 

 

 

 

 

 

87,993

 

83,010

Guidance: Prioritizing Free Cash Flow Generation and Debt Reduction

Vine’s 2021 guidance was developed to prioritize free cash flow generation and debt reduction. Average annual production is expected to be 10 – 12% higher compared to 2020 as the Company targets a one-time step-up to its optimal, long-term production goal of 1 Bcf per day.

Approximately 60% of expenditures associated with the 2021 capital program are expected to be incurred in the first six months of 2021. The program is expected to target 250,000 to 260,000 net feet of completed lateral while drilling and completion costs are expected in the range of $1,180 to $1,210 per lateral foot.

 

 

2021 (1) 

 

2nd quarter 2021 

Average Production

 

985 – 1,005 MMcfd

 

1,050 – 1,060 MMcfd

Adjusted Free Cash Flow (2)

 

$145 – $155 million

 

 

Capital Spending (incurred)

 

$340 – $350 million

 

 

Lease operating expense, per Mcf

 

$0.19 – $0.20

 

 

Gathering & treating, per Mcf

 

$0.29 – $0.30

 

 

Production & ad-valorem taxes, per Mcf

 

$0.06 – $0.07

 

 

General & administrative, per Mcf (3)

 

$0.06 – $0.07

 

 

Cash interest (4)

 

$88 – $90 million

 

$20 – $22 million

Cash income taxes (5)

 

$22 – $24 million

 

$5.0 – $5.5 million

(1)

 

Includes 1st quarter 2021 pro forma results for combined entity

(2)

 

Based on NYMEX futures on April 30, 2021; refer to the appendix for Vine’s definition of Adjusted Free Cash Flow

(3)

 

Excludes non-cash stock compensation

(4)

 

Excludes call premiums on retirement of Vine Oil & Gas LP unsecured notes

(5)

 

Includes tax distributions to original owners (financing cash flow)

Financial Position and Liquidity

As of March 31, 2021, total debt outstanding was $1.1 billion, consisting of $28 million outstanding under the 1st lien RBL, $150 million outstanding under the 2nd lien term loan, and $910 million of legacy unsecured notes issued by Vine Oil & Gas LP as the predecessor entity. Settlement of the newly issued $950 million, 6.75% 2029 senior unsecured notes did not occur until April 7, 2021. Liquidity was $389 million, in the form of cash on hand and availability under the Company’s $350 million RBL, less a $26 million letter of credit.

As of April 30, 2021, total debt outstanding was $1.2 billion, consisting of $73 million outstanding under the 1st lien RBL, $150 million outstanding under the 2nd lien term loan, and $950 million of 6.75% senior unsecured notes due 2029. Liquidity was $334 million.

In early May 2021, liquidity was enhanced by $13 million following the partial release (50%) of an outstanding letter of credit.

Hedging Update

Vine routinely utilizes commodity swaps and options to protect its development program and increase the predictability of future cash flows. As of March 31, 2021, approximately 90% of forecasted average production for April to December 2021 is hedged at a weighted average price of $2.53 per MMBtu.

The Company also engages in firm sales agreements with high-quality counterparties to effectively hedge the price received for natural gas sales at local gathering hubs. Approximately 55% of forecasted average production for April to December 2021 is presold, as follows: 30% at a weighted average price of $0.16 per MMBtu under NYMEX and 25% at $0.01 per MMBtu over Columbia Mainline.

Refer to appendix of this release for a quarterly schedule of the Company’s commodity derivative and firm sales portfolios.

Environmental, Social and Governance

Vine is committed to operating in a manner that protects the welfare of people, the environment, wildlife, and local communities. The Company proudly produces 100% natural gas to meet global demand for cleaner, sustainable, and reliable energy, while concurrently preserving ecosystems for future generations. Since 2017, Vine predecessors have reduced methane intensity by 62% and greenhouse gas intensity by 35%, with plans to realize further reductions. To learn more about Vine’s ESG leadership, visit www.vineenergy.com/commitment.

Conference Call

Date: May 17, 2021

Time: 9am Central time

Securities analysts may access an open line by dialing (844) 912-3900 (domestic U.S.) or (236) 714-3354 (international) using conference ID 5188044.

All others are encouraged to access the live webcast in listen-only mode by navigating to the following link: https://www.vineenergy.com/investors/events-and-presentations/. Note: registration required. Please access the link at least 5 minutes prior to the start of the call.

A replay of the webcast will be archived for one-year at the web address noted above.

About Vine Energy Inc.

Vine Energy Inc. (NYSE: VEI) is an energy company focused exclusively on the development of natural gas properties in the stacked Haynesville and Mid-Bossier shales in the Haynesville Basin of Northwest Louisiana. The company employs a relentless focus on generating free cash flow and shareholder returns while demonstrating environmental, social and governance leadership. For more information, visit our website at www.VineEnergy.com.

Forward-Looking Statements

The information in this Notice includes “forward-looking statements.” All statements, other than statements of historical fact included in this Notice, regarding our strategy, future operations, financial position, estimated revenue and losses, projected costs, prospects, plans and objectives of management are forward-looking statements. When used in this Notice, the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on our current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. These forward-looking statements are based on management’s current belief, based on currently available information, as to the outcome and timing of future events. We caution you that these forward-looking statements are subject to all of the risks and uncertainties, most of which are difficult to predict and many of which are beyond our control, incident to the exploration for and development, production and sale of natural gas. These risks include, but are not limited to, commodity price volatility, lack of availability of drilling and production equipment and services, costs for drilling and completion and production services, drilling and other operating risks, environmental risks, regulatory changes, the uncertainty inherent in estimating natural gas reserves and in projecting future rates of production, cash flow and access to capital, the timing of development expenditures, and other risks.

FINANCIAL STATEMENTS OF VINE ENERGY INC.

(U.S. GAAP)

 

VINE ENERGY INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands, except per share—Unaudited)

 

 

For the Three Months

Ended March 31,

 

2021

 

2020

Revenue:

 

 

 

 

Natural gas sales

 

$

153,986

 

 

$

92,543

 

Realized (loss) gain on commodity derivatives

 

 

(760

)

 

 

42,044

 

Unrealized loss on commodity derivatives

 

 

(35,103

)

 

 

(4,639

)

Total revenue

 

 

118,123

 

 

 

129,948

 

Operating Expenses:

 

 

 

 

Lease operating

 

 

14,960

 

 

 

12,995

 

Gathering and treating

 

 

20,601

 

 

 

16,382

 

Production and ad valorem taxes

 

 

3,982

 

 

 

4,149

 

General and administrative

 

 

2,583

 

 

 

3,331

 

Monitoring fee

 

 

2,077

 

 

 

1,738

 

Depletion, depreciation and accretion

 

 

97,072

 

 

 

82,324

 

Exploration

 

 

 

 

 

75

 

Strategic

 

 

 

 

 

562

 

Write-off of deferred IPO costs

 

 

 

 

 

5,787

 

Total operating expenses

 

 

141,275

 

 

 

127,343

 

Operating Income

 

 

(23,152

)

 

 

2,605

 

Interest Expense:

 

 

 

 

Interest

 

 

(29,792

)

 

 

(29,351

)

Loss on extinguishment of debt

 

 

(4,883

)

 

 

 

Total interest expense

 

 

(34,675

)

 

 

(29,351

)

Income before income taxes

 

 

(57,827

)

 

 

(26,746

)

Income tax provision

 

 

(165

)

 

 

(150

)

Net Income

 

$

(57,992

)

 

$

(26,896

)

Net income attributable to Predecessor

 

 

(28,939

)

 

 

Net income attributable to noncontrolling interest

 

 

(13,144

)

 

 

Net income attributable to Vine Energy Inc

 

 

(15,909

)

 

 

Net income per share attributable to Vine Energy Inc

 

 

 

 

Basic

 

$

(3.95

)

 

 

Diluted

 

$

(3.95

)

 

 

Weighted average shares outstanding:

 

 

 

 

Basic

 

 

4,032,450

 

 

 

Diluted

 

 

4,032,450

 

 

 

 

VINE ENERGY INC.

CONSOLIDATED BALANCE SHEETS

(Amounts in thousands—Unaudited)

 

 

March 31,

2021

 

December 31,

2020
 

Assets

 

 

 

 

Current assets:

 

 

 

 

Cash and cash equivalents

 

$

92,528

 

 

$

15,517

 

Accounts receivable

 

 

91,161

 

 

 

77,129

 

Joint interest billing receivables

 

 

17,625

 

 

 

18,280

 

Prepaid and other

 

 

1,417

 

 

 

3,626

 

Total current assets

 

 

202,731

 

 

 

114,552

 

Natural gas properties (successful efforts):

 

 

 

 

Proved

 

 

3,162,572

 

 

 

2,722,419

 

Unproved

 

 

89,993

 

 

 

 

Accumulated depletion

 

 

(1,475,582

)

 

 

(1,380,065

)

Total natural gas properties, net

 

 

1,776,983

 

 

 

1,342,354

 

Other property and equipment, net

 

 

8,828

 

 

 

7,936

 

Other

 

 

12,233

 

 

 

2,921

 

Total assets

 

$

2,000,775

 

 

$

1,467,763

 

Liabilities and Stockholders’ Equity / Partners’ Capital

 

 

 

 

Current liabilities:

 

 

 

 

Accounts payable

 

$

7,908

 

 

$

20,986

 

Accrued liabilities

 

 

141,468

 

 

 

90,004

 

Revenue payable

 

 

29,121

 

 

 

37,552

 

Derivatives

 

 

78,529

 

 

 

19,948

 

Total current liabilities

 

 

257,026

 

 

 

168,490

 

Long-term liabilities:

 

 

 

 

New RBL

 

 

28,000

 

 

 

 

Prior RBL

 

 

 

 

 

183,569

 

Second lien credit facility

 

 

143,664

 

 

 

142,947

 

Unsecured debt

 

 

899,435

 

 

 

898,225

 

Asset retirement obligations

 

 

23,467

 

 

 

21,889

 

TRA liability

 

 

6,985

 

 

 

 

Derivatives

 

 

31,447

 

 

 

38,341

 

Other

 

 

 

 

 

4,241

 

Total liabilities

 

 

1,390,024

 

 

 

1,457,702

 

Commitments and contingencies

 

 

 

 

Stockholders’ Equity / Partners’ Capital

 

 

 

 

Partners’ capital

 

 

 

 

 

10,061

 

Class A common stock, $0.01 par value, 350,000,000 shares authorized, 41,040,721 issued and outstanding at March 31, 2021

 

 

410

 

 

 

 

Class B common stock, $0.01 par value, 150,000,000 shares authorized, 34,218,535 issued and outstanding at March 31, 2021

 

 

342

 

 

 

 

Additional paid-in capital

 

 

348,406

 

 

 

 

Retained earnings

 

 

(15,909

)

 

 

Total stockholders’ equity attributable to Vine Energy Inc

 

 

333,249

 

 

 

10,061

 

Noncontrolling interest

 

 

277,502

 

 

 

 

Total stockholders’ equity / partners’ capital

 

 

610,751

 

 

 

10,061

 

Total liabilities and stockholders’ equity / partners’ capital

 

$

2,000,775

 

 

$

1,467,763

 

 

VINE ENERGY INC

CONSOLIDATED STATEMENTS OF CASH FLOW

(Amounts in thousands—Unaudited)

 

 

For the Three Months

Ended March 31,
 

 

 

2021

 

2020

Operating Activities

 

 

 

 

Net income

 

$

(57,992

)

 

$

(26,896

)

Adjustments to reconcile net income to operating cash flow:

 

 

 

 

Depletion, depreciation and accretion

 

 

97,072

 

 

 

82,324

 

Amortization of financing costs

 

 

2,909

 

 

 

4,361

 

Non-cash loss on extinguishment of debt

 

 

4,883

 

 

 

 

Non-cash write-off of deferred IPO costs

 

 

 

 

 

5,787

 

Unrealized loss on commodity derivatives

 

 

35,103

 

 

 

4,639

 

Volumetric and production adjustment to gas gathering liability

 

 

 

 

 

(2,567

)

Other

 

 

33

 

 

 

(6

)

Changes in assets and liabilities:

 

 

 

 

Accounts receivable

 

 

11,294

 

 

 

9,549

 

Joint interest billing receivables

 

 

10,084

 

 

 

(5,041

)

Accounts payable and accrued expenses

 

 

25,182

 

 

 

34,428

 

Revenue payable

 

 

(21,815

)

 

 

(6,967

)

Other

 

 

(1,442

)

 

 

530

 

Operating cash flow

 

 

105,311

 

 

 

100,141

 

Investing Activities

 

 

 

 

Cash received in acquisition of the Brix Companies

 

 

19,858

 

 

 

 

Capital expenditures

 

 

(78,013

)

 

 

(86,005

)

Investing cash flow

 

 

(58,155

)

 

 

(86,005

)

Financing Activities

 

 

 

 

Repayment of Brix Credit Facility

 

 

(127,500

)

 

 

 

Proceeds from New RBL

 

 

28,000

 

 

 

45,000

 

Payments on Prior RBL

 

 

(190,000

)

 

 

 

Proceeds from issuance of Class A common stock, net of fees

 

 

327,422

 

 

 

 

Deferred financing costs

 

 

(8,067

)

 

 

(3,848

)

Financing cash flow

 

 

29,855

 

 

 

41,152

 

Net increase in cash and cash equivalents

 

 

77,011

 

 

 

55,288

 

Cash and cash equivalents at beginning of period

 

 

15,517

 

 

 

18,286

 

Cash and cash equivalents at end of period

 

$

92,528

 

 

$

73,574

 

FINANCIAL STATEMENTS OF VINE ENERGY INC.

(Pro Forma)

To facilitate a clearer representation of first-quarter 2021 performance, all schedules presented hereinafter are pro forma for the combination resulting from the corporate reorganization and initial public offering as if the transactions occurred on January 1, 2020.  

VINE ENERGY INC.

UNAUDITED PRO FORMA STATEMENTS OF OPERATIONS

 

 

For the Three Months

Ended March 31,

 

 

2021

 

2020

Revenue:

 

 

 

 

Natural gas sales

 

$

200,927

 

 

$

128,296

 

Realized gain (loss) on derivatives

 

 

(2,348

)

 

 

58,305

 

Unrealized loss on derivatives

 

 

(37,949

)

 

 

(5,437

)

Total revenue

 

 

160,630

 

 

 

181,164

 

Operating Expenses:

 

 

 

 

Lease operating

 

 

18,693

 

 

 

15,725

 

Gathering and treating

 

 

26,296

 

 

 

22,654

 

Production and ad valorem taxes

 

 

4,757

 

 

 

4,951

 

General and administrative

 

 

3,954

 

 

 

5,453

 

Depletion, depreciation and accretion

 

 

106,505

 

 

 

93,457

 

Exploration

 

 

1

 

 

 

75

 

Strategic costs

 

 

 

 

 

717

 

Write-off of deferred IPO expenses

 

 

 

 

 

5,787

 

Total operating expenses

 

 

160,206

 

 

 

148,819

 

Operating Income

 

 

424

 

 

 

32,345

 

Interest expense

 

 

(34,249

)

 

 

(27,284

)

Income Before Income Taxes

 

 

(33,825

)

 

 

5,061

 

Income tax provision

 

 

(165

)

 

$

(150

)

Net Income

 

$

(33,990

)

 

$

4,911

 

Net income attributable to non-controlling interests

 

 

(15,390

)

 

 

2,303

 

Net Income Attributable to Vine Energy Inc

 

 

(18,600

)

 

 

2,608

 

Net Income per Share:

 

 

 

 

Basic

 

$

(0.45

)

 

$

0.06

 

Diluted

 

$

(0.45

)

 

$

0.06

 

Weighted Average Shares Outstanding:

 

 

 

 

Basic

 

 

41,040,721

 

 

 

41,040,721

 

Diluted

 

 

41,040,721

 

 

 

41,040,721

 

VINE ENERGY INC

SELECT PRO FORMA PRODUCTION AND UNIT COSTS STATISTICS

 

 

For the Three Months

Ended Mar 31,
 

 

 

2021

 

2020

Production data:

 

 

 

 

Natural gas (MMcf)

 

 

85,035

 

 

78,207

 

Average daily production (MMcfd)

 

 

945

 

 

859

 

Average sales prices per Mcf:

 

 

 

 

Before effects of derivatives

 

$

2.36

 

$

1.64

 

After effects of derivatives

 

 

2.34

 

 

2.39

 

Costs per Mcf:

 

 

 

 

Lease operating

 

$

0.22

 

$

0.20

 

Cash gathering and treating

 

 

0.31

 

 

0.32

 

Production and ad valorem taxes

 

 

0.06

 

 

0.06

 

General and administrative

 

 

0.05

 

 

0.07

 

Total cash operating expenses

 

$

0.63

 

$

0.66

 

Exploration

 

 

0.00

 

 

0.00

 

Depreciation, depletion and accretion

 

 

1.25

 

 

1.19

 

Strategic

 

 

 

 

0.01

 

Non-cash gain on gathering liability

 

 

 

 

(0.03

)

Non-cash writeoff of deferred IPO costs

 

 

 

 

0.07

 

Total (may not foot due to rounding)

 

$

1.88

 

$

1.90

 

VINE ENERGY INC.

NATURAL GAS SWAPS

 

 

Natural Gas

Swaps

 

Weighted Avg

Swap Price

Period

 

(MMBtud) 

 

($ / MMBtu) 

2021

 

 

 

 

Second Quarter

 

832,871

 

$

2.52

Third Quarter

 

845,333

 

$

2.53

Fourth Quarter

 

848,887

 

$

2.55

2022

 

 

 

 

First Quarter

 

866,797

 

$

2.56

Second Quarter

 

348,859

 

$

2.54

Third Quarter

 

409,853

 

$

2.54

Fourth Quarter

 

604,935

 

$

2.53

2023

 

 

 

 

First Quarter

 

528,652

 

$

2.48

Second Quarter

 

65,470

 

$

2.45

Third Quarter

 

45,954

 

$

2.44

Fourth Quarter

 

125,092

 

$

2.50

2024

 

 

 

 

First Quarter

 

313,512

 

$

2.53

Second Quarter

 

11,957

 

$

2.31

Third Quarter

 

7,366

 

$

2.31

Fourth Quarter

 

70,761

 

$

2.58

2025

 

 

 

 

First Quarter

 

137,667

 

$

2.58

VINE ENERGY INC.

FIRM SALES

Period

 

Firm Sales:

NYMEX Index

(MMBtud)

 

Weighted Avg Price

(NYMEX less)

($ / MMBtu)

 

Firm Sales:

ML Index

(MMBtud)
 

 

Weighted Avg Price

(ML plus)

($ / MMBtu) 

2021

 

 

 

 

 

 

 

 

Second Quarter

 

405,067

 

$

(0.163

)

 

467,171

 

$

0.012

Third Quarter

 

310,000

 

$

(0.163

)

 

355,202

 

$

0.013

Fourth Quarter

 

310,000

 

$

(0.163

)

 

138,401

 

$

0.014

2022

 

 

 

 

 

 

 

 

First Quarter

 

310,000

 

$

(0.163

)

 

30,000

 

$

0.015

Second Quarter

 

100,000

 

$

(0.150

)

 

30,000

 

$

0.015

Third Quarter

 

100,000

 

$

(0.150

)

 

30,000

 

$

0.015

Fourth Quarter

 

33,333

 

$

(0.150

)

 

30,000

 

$

0.015

2023

 

 

 

 

 

 

 

 

First Quarter

 

 

 

 

 

30,000

 

$

0.015

FINANCIAL STATEMENTS OF VINE ENERGY INC.

(Reconciliation)

NON-GAAP FINANCIAL MEASURES

We define Adjusted EBITDAX as our net income before interest expense, income taxes, depreciation, depletion and accretion, unrealized gains and losses on commodity derivatives, exploration expense, strategic expense, and other non-cash operating items. We believe Adjusted EBITDAX is a useful performance measure because it allows for an effective valuation of our operating performance when compared against our peers, without regard to our financing methods, corporate form, or capital structure. We exclude the items listed above in arriving at Adjusted EBITDAX to reflect the substantial variance in practice from company to company within our industry depending upon accounting methods and book values of assets, capital structures and the method by which the assets were acquired. Adjusted EBITDAX should not be considered as an alternative to, or more meaningful than, net income determined in accordance with GAAP. Certain items excluded from Adjusted EBITDAX are significant components in understanding and assessing a company’s financial performance, such as a company’s cost of capital and tax burden, as well as the historic costs of depreciable assets, none of which are reflected in Adjusted EBITDAX. Our presentation of Adjusted EBITDAX should not be construed as an inference that our results will be unaffected by unusual or non-recurring items. Our computations of Adjusted EBITDAX may not be identical to other similarly titled measures of other companies.

We define Adjusted Free Cash Flow as Adjusted EBITDAX less the sum of cash interest, capital incurred and tax payments and distributions. We believe Adjusted Free Cash Flow is a useful performance measure as it’s an indicator of the company’s ability to generate cash flow once capital is invested to either maintain or expand production. Adjusted Free Cash Flow should not be considered as an alternative to, or more meaningful than, operating cash flow or investing cash flow determined in accordance with GAAP. Our computation of adjusted free cash flow may not be identical to other similarly titled measures of other companies.

VINE ENERGY INC.

RECONCILIATION OF NET INCOME TO ADJUSTED EBITDAX AND ADJUSTED FREE CASH FLOW

 

 

Pro Forma Presentation

 

GAAP Presentation 

 

 

For the Three Months

Ended Mar 31,

 

For the Three Months

Ended Mar 31,

 

 

 

2021

 

 

 

2020

 

 

 

2021

 

 

 

2020

 

 

 

(in thousands)

 

(in thousands)

Net income/(loss)

 

$

(33,990

)

 

$

4,911

 

 

$

(57,992

)

 

$

(26,896

)

Interest expense

 

 

34,249

 

 

 

27,284

 

 

 

34,675

 

 

 

29,351

 

Income tax provision

 

 

165

 

 

 

150

 

 

 

165

 

 

 

150

 

Depletion, depreciation and accretion

 

 

106,505

 

 

 

93,457

 

 

 

97,072

 

 

 

82,324

 

Unrealized (gain)/loss on commodity derivatives

 

 

37,949

 

 

 

5,437

 

 

 

35,103

 

 

 

4,639

 

Exploration

 

 

1

 

 

 

75

 

 

 

 

 

 

75

 

Non-cash G&A

 

 

 

 

 

344

 

 

 

(1

)

 

 

(6

)

Strategic

 

 

 

 

 

717

 

 

 

 

 

 

562

 

Non-cash writeoff of deferred IPO costs

 

 

 

 

 

5,787

 

 

 

 

 

 

5,787

 

Non-cash volumetric and production adjustment to gas gathering liability

 

 

 

 

 

(2,567

)

 

 

 

 

 

(2,567

)

Adjusted EBITDAX

 

$

144,879

 

 

$

135,595

 

 

$

109,022

 

 

$

93,419

 

Cash interest

 

 

(26,588

)

 

 

(24,242

)

 

 

(26,770

)

 

 

(24,990

)

Capital incurred

 

 

(97,828

)

 

 

(99,021

)

 

 

(81,168

)

 

 

(82,290

)

Adjusted Free Cash Flow

 

$

20,463

 

 

$

12,332

 

 

$

1,084

 

 

$

(13,861

)

 

Investor Contact Information

David Erdman

Director, Investor Relations

Phone: 469-605-2480

Email: [email protected]

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Energy Utilities Oil/Gas

MEDIA:

Logo
Logo

AAON Announces Semi-Annual Cash Dividend and Promotion of Christopher D. Eason

TULSA, Okla., May 17, 2021 (GLOBE NEWSWIRE) — AAON, Inc. (NASDAQ-AAON), today announced that its Board of Directors has declared the Company’s next regular semi-annual cash dividend of $0.19 per share (or $0.38 annually), payable on July 1, 2021 to stockholders of record as of the close of business on June 3, 2021.

The Company also announced today that its Board of Directors has promoted Christopher D. Eason to the position of Chief Accounting Officer, effective May 11, 2021.

Christopher D. Eason, 39, joined AAON in 2018 as Controller and Financial Reporting Manager. Prior to joining the Company, he served as a Senior Manager at Grant Thornton, LLP, where he had 13 years of experience in the assurance division. Mr. Eason is a licensed certified public accountant and graduated from Oklahoma State University with a Bachelor of Science and Master of Science in Accounting.

Gary D. Fields, President and CEO, stated, “Please join me in congratulating Chris on his promotion to Chief Accounting Officer. This promotion is the latest example of our ongoing succession planning initiatives. Chris has been a trusted member of our accounting / financial reporting department since 2018, and I am confident he will continue to have a positive impact at AAON as he assumes this new role.”

About AAON

AAON, Inc. is engaged in the engineering, manufacturing, marketing and sale of air conditioning and heating equipment consisting of standard, semi-custom and custom rooftop units, chillers, packaged outdoor mechanical rooms, air handling units, makeup air units, energy recovery units, condensing units, geothermal/water-source heat pumps, coils and controls. Since the founding of AAON in 1988, AAON has maintained a commitment to design, develop, manufacture and deliver heating and cooling products to perform beyond all expectations and demonstrate the value of AAON to our customers. For more information, please visit www.AAON.com.

Certain statements in this news release, which are not historical facts, are “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements about AAON’s estimates, expectations, beliefs, intentions or strategies for the future, and the assumptions underlying these forward-looking statements, including, but not limited to, future financial performance, future opportunities and any other statements regarding events, opportunities or developments that AAON believes or reasonably anticipates will or may occur in the future, including potential financial and operational impacts of COVID-19. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “will”, “should”, “outlook”, “projected” and variations of such words and similar expressions are intended to identify these forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. AAON undertakes no obligation to disseminate any updates or revisions to any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by federal securities laws. Forward-looking statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions which are difficult to predict, including but not limited to economic, competitive, governmental and technological factors impacting AAON’s operations, supply chains, markets, products, services and prices. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” and “Forward-Looking Statements” in AAON’s Annual Report on Form 10-K for the most recent fiscal year, as may be revised and updated by AAON’s Quarterly Reports on Form 10-Q, and AAON’s Current Reports on Form 8-K.

Contact Information

Joseph Mondillo
Director of Investor Relations
Phone: (617) 877-6346
Email: [email protected]



Orthofix Announces US and European Full Market Launch of OSCAR PRO System for Removal of Cement During Complex Joint Revision Surgeries

Orthofix Announces US and European Full Market Launch of OSCAR PRO System for Removal of Cement During Complex Joint Revision Surgeries

LEWISVILLE, Texas–(BUSINESS WIRE)–Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced the U.S. and European full market launch of the OSCAR PROUltrasonic Arthroplasty Revision System. Designed to reduce the challenges associated with revising failed cemented arthroplasties, the OSCAR PRO is an ultrasonic surgical system that aids in the removal of cement during complex joint revision surgeries.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210517005198/en/

OSCAR PRO™ system for arthroplasty procedures and osteotomies. (Photo: Business Wire)

OSCAR PRO™ system for arthroplasty procedures and osteotomies. (Photo: Business Wire)

“The OSCAR PRO system is a fourth generation product from the OSCAR line that has been the gold standard in assisting with complex joint revision surgeries since 1990,” said Orthofix President of Global Orthopedics Paul Gonsalves. “The technology is well accepted and has been used successfully for decades in removing cement total joint arthroplasties and aiding cementless prosthesis removal. We are pleased to continue to bring new innovations to the market to assist surgeons in performing these often challenging procedures.”

This next generation product brings a technology platform to the market that extends functionalities beyond the original OSCAR system. The design includes an enhanced user interface to enable a more efficient surgical experience and new data collection capabilities.

About Joint Revision Surgery

Over time, joint replacements may fail and need surgical revision. Removing the implant can be challenging due to the need to efficiently remove the cement adhering the device to the bone. Traditional techniques for cement removal have included the use of drills, burrs, curettes and osteotomes. Mechanical removal through these methods can be difficult and time-consuming. The OSCAR PRO system uses ultrasonic vibrations to soften the cement holding the implant in place. The system also contains tools that enable the surgeon to remove the softened cement using specially designed probes.

About Orthofix

Orthofix Medical Inc. is a global medical device and biologics company with a spine and orthopedics focus. The Company’s mission is to deliver innovative, quality-driven solutions as we partner with health care professionals to improve patient mobility. Headquartered in Lewisville, Texas, Orthofix’s spine and orthopedic products are distributed in more than 70 countries via the Company’s sales representatives and distributors. For more information, please visit www.Orthofix.com.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, relating to our business and financial outlook, which are based on our current beliefs, assumptions, expectations, estimates, forecasts and projections. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “intends,” “predicts,” “potential,” or “continue” or other comparable terminology. These forward-looking statements are not guarantees of our future performance and involve risks, uncertainties, estimates and assumptions that are difficult to predict, including the risks described in Part I, Item 1A under the heading Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2020 (the “2020 Form 10-K”). In addition to the risks described there, factors that could cause or contribute to such differences may include, but are not limited to; the risk that surgeons may be slow to adopt the OSCAR PRO system; the risk that future patient studies or clinical experience and data may indicate that treatment with the OSCAR PRO system does not improve patient outcomes as much as previously believed, or otherwise call into question the benefits of its use to patients, hospitals and surgeons; the risk that the product may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that insurance payers may decline to reimburse healthcare providers for the use of our products.

This list of risks, uncertainties and other factors is not complete. We discuss some of these matters more fully, as well as certain risk factors that could affect our business, financial condition, results of operations, and prospects, in reports we file from time-to-time with the SEC, which are available to read at www.sec.gov. Any or all forward-looking statements that we make may turn out to be wrong (due to inaccurate assumptions that we make or otherwise), and our actual outcomes and results may differ materially from those expressed in these forward-looking statements. You should not place undue reliance on any of these forward-looking statements. Further, any forward-looking statement speaks only as of the date hereof, unless it is specifically otherwise stated to be made as of a different date. We undertake no obligation to update, and expressly disclaim any duty to update, our forward-looking statements, whether as a result of circumstances or events that arise after the date hereof, new information, or otherwise.

Alexa Huerta

Investor Relations

Tel 214 937 3190

[email protected]

Denise Landry

Media Relations

Tel 214 937 2529

[email protected]

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Surgery Health Medical Devices

MEDIA:

Logo
Logo
Photo
Photo
OSCAR PRO™ system for arthroplasty procedures and osteotomies. (Photo: Business Wire)

Medivolve Expands Portfolio of Pharmacy Acquisitions with Agreement to Acquire Outstanding Shares of CalVax Licensed Marbella Pharmacy

Acquisition will give Medivolve immediate access to pharmaceutical distribution and CalVax licensing throughout CA;
near term COVID-19 vaccination allocations to follow

TORONTO, May 17, 2021 (GLOBE NEWSWIRE) — Medivolve Inc. (“Medivolve”) (NEO:MEDV; OTC:COPRF; FRA:4NC) a healthcare technology and services company, today announced it has signed a binding agreement to acquire 100% of all outstanding shares of Marbella, a nonsterile compounded California state licensed and insured pharmacy. This acquisition advances Medivolve’s growth strategy and expands its ability to deliver patient care through immediate access to pharmaceutical distribution throughout the state of California.

“The acquisition of Marbella Pharmacy is an important step forward in executing on our strategic growth strategy,” said David Preiner, CEO of Medivolve. “With Marbella, we have access to distribute pharmaceuticals, and soon COVID-19 vaccinations in the fifth-largest economy in the world. We will continue to invest in the resources and partnerships that advance our mission to harness the transformative power of technology to help more people live healthier lives.”

Located in San Juan Capistrano, California, Marbella is an open-door retail pharmacy specializing in traditional medication and non-sterile compounded products, immunizations, and specialty and maintenance medications. Marbella Pharmacy also provides no cost door-to-door prescription delivery service and is reputed for servicing the underserved and worker’s compensation patients. The pharmacy is CalVax approved and is eligible to participate in the California COVID-19 Vaccination. It is in the process of attaining vaccine allocations from the State of California.

“Attaining the CalVax licensing was an important milestone in authorizing us to administer vaccinations to our immediate customer base in the San Juan Capistrano area. Now, in partnership with Medivolve, we can extend our medical care, diagnostic testing and vaccination services across the state of California, practically overnight,” said James Harmon, CEO, and owner of Marbella Pharmacy. “We are pleased to be partnering with Medivolve in a joint mission to increase healthcare accessibility, reliability and efficiency for more people at this critical time in our history.”

This news comes on the heels of two announcements key to the company’s strategic growth plans last week. First, Medivolve announced, along with Marvel Diagnostics, that BlowFISH, a non-invasive exhaled breath diagnostic technology for COVID-19, has successfully completed first stage clinical testing. The company believes the technology has implications for a variety of respiratory illnesses and is aligned with its goal to pursue massively deployable solutions that improve human health over the long-term. Medivolve also announced that it has signed an agreement to acquire a 100% interest in the Electronic Health Record application and all associated intellectual property from Myosin. According to Medivolve, the development of the app is key to the company’s goal of creating a subscription-based model where users and clinicians can access a singular health management platform under the Medivolve umbrella.

Medivolve also announces the cancellation of the previously announced binding Letter of Intent to acquire a 100% equity interest in Modern Rx LLC (see the Company’s press release dated March 16, 2021). Medivolve has determined that the acquisition of the Marbella Pharmacy will be a better fit for the Company’s business going forward.

About the Transaction

Medivolve will acquire 100% of all outstanding shares of Marbella Pharmacy from the shareholders of the company. In consideration for the acquisition of the Marbella Shares, Medivolve shall pay to Marbella Pharmacy shareholders: (i) a cash payment of US$200,000 payable 60 days following the closing; (ii) a working capital cash payment of US$75,000 payable 75 days post closing; and (iii) the issuance of 2,000,000 Medivolve Common Shares.   The completion of the transaction to acquire 100% of the Marbella pharmacy is subject to customary closing conditions and NEO Stock Exchange approval. No finder fees are payable in connection with, and no change of control of Medivolve will result from, the transaction.

About Medivolve Inc.

Medivolve Inc. (NEO:MEDV; OTC:COPRF; FRA:4NC) focuses on finding and developing disruptive technologies, ground-breaking innovations and exclusive partnerships to help combat COVID-19 and transform human health management. This includes providing convenient and accessible medical services for testing, prevention and treatment. Medivolve is comprised of a team of renowned global medical and business advisors who are committed to helping fulfill Medivolve’s mission of searching for and investing in breakthrough sciences, technologies, research, or resolutions to empower the betterment of mankind. This panel includes prominent Stanford neurologist and immunologist Dr. Lawrence Steinman as well as Dr. Glenn Copeland, one of North America’s most prominent orthopedic treatment and sports medicine specialists.

For investing inquiries, please contact: 
[email protected]  
  
For U.S. media inquiries, please contact: 
Sophia Powe 
[email protected] 
  
Cautionary Note Regarding Forward-looking Information
  
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the acquisition of the Marbella Pharmacy; the cancellation of the transaction to acquire the Modern Rx Pharmacy; the benefits and opportunities related to the Marbella Pharmacy; the pursuit by Medivolve of opportunities; and the merits or potential returns of any such opportunities, including the Company’s investment in Marvel Diagnostics. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
  
NEITHER THE NEO EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. 



OraSure Technologies Appoints Scott Gleason As Senior Vice President Investor Relations and Corporate Communications

BETHLEHEM, Pa., May 17, 2021 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that Scott Gleason has been appointed Senior Vice President Investor Relations and Corporate Communications effective today.

Prior to joining OraSure, Mr. Gleason served as the Senior Vice President of Investor Relations and Corporate Strategy for Myriad Genetics, Inc., a leading specialty diagnostic laboratory in the United States focused on genetic testing and precision medicine. At Myriad, he managed the investor relations and corporate communications functions, led the annual strategic planning process, and was a member of the Company’s strategic committee. Prior to his tenure with Myriad Genetics, Mr. Gleason was a senior publishing analyst at Stephens, Inc. from 2005 to 2013 covering the life science tools and diagnostics industry. Before joining Stephens, Inc. Mr. Gleason was a United States Air Force aircraft maintenance officer and participated in two wartime deployments. Mr. Gleason received a Bachelor of Science degree from the U.S. Air Force Academy in Colorado Springs, CO. 

“We are delighted to welcome Scott as the Company’s new Senior Vice President Investor Relations and Corporate Communications. Scott comes to OraSure with over 20 years of executive leadership experience focused in investment banking, investor relations, corporate communications, and corporate strategy and business development.  His extensive experience gives him a unique insight that will make him a strong addition to OraSure’s executive team as the Company advances its work to help solve the world’s greatest health challenges,” said Stephen S. Tang, Ph.D., President and CEO of OraSure Technologies.

About OraSure Technologies

OraSure Technologies, Inc. (NASDAQ: OSUR) empowers the global community to improve health and wellness by providing access to accurate, essential information. Together with its wholly owned subsidiaries, DNA Genotek, Diversigen and Novosanis, OraSure provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. For more information on OraSure Technologies, please visit www.orasure.com.

Investor Contact:
Sam Martin
Argot Partners
212-600-1902
[email protected]
Media Contact:
Jeanne Mell
VP Corporate Communications
484-353-1575
[email protected]



Hims & Hers Health, Inc. Reports First Quarter 2021 Financial Results

Hims & Hers Health, Inc. Reports First Quarter 2021 Financial Results

Q1 2021 revenue grows 74% year-over-year to $52.3 million

Q1 2021 gross margin of 77% compared to 69% in Q1 2020

Exceeds Q1 2021 guidance, raises full year 2021 revenue expectations

SAN FRANCISCO–(BUSINESS WIRE)–
Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, today reported financial results for the first quarter ending March 31, 2021.

“Building on our momentum from last year, Hims & Hers kicked off 2021 with a very strong first quarter, delivering robust revenue growth of 74%, gross profit growth of 95%, and ending the quarter with 391,000 subscriptions on our platform, up nearly 80% year-over-year,” said Andrew Dudum, CEO and co-founder of Hims & Hers. “We made significant headway on our mission of making the highest quality, personalized healthcare accessible to everyone, and we continued to set ourselves apart in the industry with our unified and fully verticalized front door to care.”

Mr. Dudum continued, “It’s our unique ability to anticipate what’s next, to meet our target consumers where they are, and to deliver a beautiful, digital experience that keeps us at the forefront of the transformation of healthcare.”

Key Business Metrics

(In Thousands, Except AOV)

 

Three Months Ended

 

March 31, 2021

 

December 31, 2020

 

September 30, 2020

 

June 30, 2020

 

March 31, 2020

 

 

 

 

 

 

 

 

 

 

AOV

$

74

 

 

$

69

 

 

$

67

 

 

$

58

 

 

$

52

 

Net Orders

687

 

 

579

 

 

582

 

 

572

 

 

546

 

Revenue

(In Thousands, Unaudited)

 

Three Months Ended

 

March 31, 2021

 

December 31, 2020

 

September 30, 2020

 

June 30, 2020

 

March 31, 2020

 

 

 

 

 

 

 

 

 

 

Online Revenue

$

50,680

 

 

$

40,091

 

 

$

38,829

 

 

$

33,284

 

 

$

28,524

 

Wholesale Revenue

1,634

 

 

1,375

 

 

2,495

 

 

2,620

 

 

1,539

 

Total revenue

$

52,314

 

 

$

41,466

 

 

$

41,324

 

 

$

35,904

 

 

$

30,063

 

Total revenue year-over-year growth

74

%

 

67

%

 

91

%

 

76

%

 

91

%

  • Revenue was $52.3 million for the first quarter 2021 compared to $30.1 million for the first quarter 2020, an increase of 74% year-over-year.
  • Net loss was $(51.4) million for the first quarter 2021 compared to $(6.0) million for the first quarter 2020. The year-over-year increase in net loss was primarily driven by one-time stock-based compensation and transaction bonus expenses related to the merger with Oaktree Acquisition Corp.
  • Gross margin was 77% for the first quarter 2021 compared to 69% for the first quarter 2020.
  • Adjusted EBITDA was $(8.6) million for the first quarter 2021 compared to $(4.6) million for the first quarter 2020.

A reconciliation of Adjusted EBITDA, a non-GAAP measure, to net loss, its most comparable financial measure under generally accepted accounting principles in the United States (“U.S. GAAP”), has been provided in this press release in the accompanying tables. Additional information about Adjusted EBITDA is also included below under the heading “Non-GAAP Financial Measures”.

Financial Outlook

Hims & Hers provides guidance based on current market conditions and expectations for revenue and Adjusted EBITDA, which is a non-GAAP financial measure.

For the second quarter 2021, we expect:

  • Revenue to be in the range of $55 million to $57 million.
  • Adjusted EBITDA to be in the range of $(10) million to $(12) million.

For the full year 2021, we expect:

  • Revenue to be in the range of $221 million to $227 million.
  • Adjusted EBITDA to be in the range of $(35) million to $(45) million.

The guidance provided above constitutes forward-looking statements and actual results may differ materially. Refer to the “Cautionary Note Regarding Forward-Looking Statements” safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.

We have not reconciled forward-looking Adjusted EBITDA to its most directly comparable U.S. GAAP measure, net loss, because we cannot predict with reasonable certainty the ultimate outcome of certain components of such reconciliations, including market-related assumptions that are not within our control, or others that may arise, without unreasonable effort. For these reasons, we are unable to assess the probable significance of the unavailable information, which could materially impact the amount of future net loss. See “Non-GAAP Financial Measures” for additional important information regarding Adjusted EBITDA.

Conference Call

Hims & Hers will host a conference call to review the first quarter 2021 results on May 18, 2021, at 2:00 p.m. PT. The conference call can be accessed by dialing (833) 900-2256 for U.S. participants and (236) 714-2727 for international participants, and referencing conference ID #8982901. A live audio webcast will be available online at https://investors.forhims.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call at the same link.

About Hims & Hers Health, Inc.

Hims & Hers is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to primary care, mental health, sexual health, dermatology, and more. Launched in November 2017, the company also offers thoughtfully created and curated health and wellness products. With products and services available across all 50 states and Washington, D.C., Hims & Hers is able to provide access to quality, convenient and affordable care for all Americans. Hims & Hers was founded by CEO Andrew Dudum, Hilary Coles, Jack Abraham and Joe Spector at venture studio Atomic in San Francisco, California. For more information about Hims & Hers, please visit forhims.com and forhers.com.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “may,” “will,” “potential,” “projects,” “predicts,” “continue,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, any statements relating to our financial outlook and guidance, financial and business performance, the underlying assumptions, and statements about events and trends including events and trends that we believe may affect our financial condition, results of operations, short- and long-term business operations and objectives, and financial needs, market acceptance and success of our business model, our ability to expand the scope of our offerings, and our ability to comply with the extensive, complex and evolving regulatory requirements applicable to the healthcare industry. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.

The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the “Risk Factors” section of our most recently filed Annual Report on Form 10-K for the year ended December 31, 2020, as amended, and our subsequent filings with the Securities and Exchange Commission (the “Commission”).

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in reports we have filed or will file with the Commission, including our annual report on Form 10-K for the year ended December 31, 2020, as amended and our subsequent filings with the Commission. In addition, even if our results of operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in such reports, those results or developments may not be indicative of results or developments in subsequent periods.

Key Business Metrics

Average Order Value (“AOV”) is defined as Online Revenue divided by Net Orders (each as defined below).

“Net Orders” are defined as the number of online customer orders minus transactions related to refunds, credits, chargebacks, and other negative adjustments. Net Orders represent transactions made on our platform during a defined period of time and exclude revenue recognition adjustments recorded pursuant to U.S. GAAP.

“Online Revenue” represents the sales of products and services on our platform, net of refunds, credits, chargebacks and includes revenue recognition adjustments recorded pursuant to U.S. GAAP, primarily relating to deferred revenue and returns reserve.

“Wholesale Revenue” represents non-prescription product sales to retailers through wholesale purchasing agreements.

 

CONDENSED CONSOLIDATED BALANCE SHEETS

(In Thousands, Except Share and Per Share Data)

 

 

March 31,

2021

 

December 31,

2020

 

(Unaudited)

 

 

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

88,169

 

 

$

27,344

 

Short-term investments

235,097

 

 

72,864

 

Inventory

4,523

 

 

3,543

 

Prepaid expenses and other current assets

12,407

 

 

5,404

 

Deferred transaction costs

 

 

3,929

Total current assets

340,196

 

 

113,084

 

Restricted cash, noncurrent

856

 

 

1,006

Other long-term assets

4,848

 

 

4,607

 

Total assets

$

345,900

 

 

$

118,697

 

 

 

 

 

Liabilities, mezzanine equity, and stockholders’ equity (deficit)

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

13,233

 

 

$

8,066

 

Accrued liabilities

5,823

 

 

4,984

 

Deferred revenue

624

 

 

1,272

Warrant liabilities

 

906

 

Total current liabilities

19,680

 

 

15,228

 

Warrant liabilities

33,370

 

Deferred rent, noncurrent

384

 

381

Total liabilities

53,434

 

 

15,609

 

 

 

 

 

Commitments and contingencies

 

 

 

 

 

 

 

Mezzanine equity:

 

 

 

Redeemable convertible preferred stock par value $0.0001, 275,000,000 and 95,997,674 shares authorized and nil and 93,328,118 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively; liquidation preference of nil and $268,452 as of March 31, 2021 and December 31, 2020, respectively

 

249,962

 

Total mezzanine equity

 

 

249,962

 

 

 

 

 

Stockholders’ equity (deficit):

 

 

 

Common stock – Class A shares, par value $0.0001, 2,750,000,000 and 166,696,759 shares authorized and 182,973,780 and 46,025,754 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively; Class V shares, par value $0.0001, 10,000,000 shares authorized and 8,377,623 shares issued, and outstanding as of March 31, 2021; Class F shares, par value $0.0001, 6,941,352 shares authorized, issued, and outstanding as of December 31, 2020

18

 

Additional paid-in capital

515,216

 

 

24,429

 

Accumulated other comprehensive loss

(72)

 

 

(11)

Accumulated deficit

(222,696)

 

 

(171,292)

 

Total stockholders’ equity (deficit)

292,466

 

 

(146,874)

 

Total liabilities, mezzanine equity, and stockholders’ equity (deficit)

$

345,900

 

 

$

118,697

 

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In Thousands, Except Share and Per Share Data, Unaudited)

 

 

Three Months Ended

March 31,

 

2021

 

2020

 

 

 

 

Revenue

$

52,314

 

$

30,063

 

Cost of revenue

12,067

 

9,444

 

Gross profit

40,247

 

20,619

 

Gross margin %

77

%

69

%

 

 

 

Operating expenses:(1)

 

 

Marketing

26,958

 

12,773

 

Selling, general, and administrative

61,698

 

14,064

 

Total operating expenses

88,656

 

26,837

 

Loss from operations

(48,409)

 

(6,218)

 

 

 

 

Other income (expense):

 

 

Interest expense

 

(10)

 

Other (expense) income, net

(2,905)

 

230

 

Loss before provision for income taxes

(51,314)

 

(5,998)

 

Provision for income taxes

(90)

 

(35)

 

Net loss

(51,404)

 

(6,033)

 

Other comprehensive loss

(61)

 

(42)

 

Total comprehensive loss

$

(51,465)

 

$

(6,075)

 

 

 

 

Net loss per share attributable to common stockholders:

 

 

Basic and diluted

$

(0.34)

 

$

(0.17)

 

Weighted average shares outstanding:

 

 

Basic and diluted

153,080,538

34,610,061

______________

(1)

Includes stock-based compensation expense as follows (in thousands):

 

Three Months Ended

March 31,

 

2021

2020

Marketing

$

1,846

 

$

291

 

Selling, general, and administrative

32,384

 

1,113

 

Total stock-based compensation expense

$

34,230

 

$

1,404

 

 

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In Thousands, Unaudited)

 

 

Three Months Ended

March 31,

 

2021

 

2020

Operating activities

 

 

 

Net loss

$

(51,404)

 

 

$

(6,033)

 

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

Depreciation and amortization

394

 

 

180

 

Stock-based compensation

34,230

 

 

1,404

 

Change in fair value of warrant liabilities

2,681

 

 

(71)

 

Warrant expense in connection with Merger

154

 

 

 

Amortization of debt issuance costs

144

 

 

84

 

Noncash other

452

 

 

(16)

 

Changes in operating assets and liabilities:

 

 

 

Inventory

(980)

 

 

(2,000)

 

Prepaid expenses and other current assets

(7,147)

 

 

(471)

 

Other long-term assets

(58)

 

 

733

 

Accounts payable

5,117

 

 

674

 

Accrued liabilities

1,114

 

 

199

 

Deferred revenue

(648)

 

 

126

 

Deferred rent

3

 

 

 

Net cash used in operating activities

(15,948)

 

 

(5,191)

 

 

 

 

 

Investing activities

 

 

 

Purchases of investments

(172,021)

 

 

(17,642)

 

Maturities of investments

9,500

 

 

19,200

 

Proceeds from sales of investments

 

 

6,400

 

Investment in website development and internal-use software

(740)

 

 

(452)

 

Purchases of property, equipment, and intangible assets

(63)

 

 

(273)

 

Net cash (used in)/provided by investing activities

(163,324)

 

 

7,233

 

 

 

 

 

Financing activities

 

 

 

Proceeds from issuance of redeemable convertible preferred stock

 

 

31,600

 

Payments for issuance costs of convertible preferred stock

 

 

(89)

 

Pre-closing stock repurchase

(22,027)

 

 

 

Proceeds from issuance of common stock upon Merger

197,686

 

 

 

Proceeds from PIPE

75,000

 

 

 

Payments for transaction costs

(12,794)

 

 

 

Repayment of promissory notes associated with vested and unvested shares

1,193

 

 

 

Proceeds from exercise of Class A common stock warrants

807

 

 

 

Proceeds from exercise of vested and unvested stock options, net of repurchases

80

 

 

(18)

 

Repayments of principal on term loan

 

 

(1,158)

 

Net cash provided by financing activities

239,945

 

 

30,335

 

Foreign currency effect on cash and cash equivalents

2

 

 

(9)

 

Increase in cash, cash equivalents, and restricted cash

60,675

 

 

32,368

 

Cash, cash equivalents, and restricted cash at beginning of the year

28,350

 

 

22,797

 

Cash, cash equivalents, and restricted cash at end of the three-month period

$

89,025

 

 

$

55,165

 

 

 

 

 

Supplemental disclosures of cash flow information

 

 

 

Cash paid for taxes

$

59

 

 

$

69

 

Cash paid for interest

$

 

 

$

8

 

Noncash investing and financing activities

 

 

 

Recapitalization of redeemable convertible preferred stock from pre-closing stock repurchase

$

125

 

 

$

 

Conversion of redeemable convertible preferred stock to common stock

$

249,837

 

 

$

 

Assumption of Merger warrants liability

$

51,814

 

 

$

 

Exercise of Private Placement Warrants and Public Warrants

$

20,871

 

 

$

 

Reclassification of deferred transaction costs

$

3,929

 

 

$

 

Conversion of Series D preferred stock warrants to Class A common warrants

$

1,160

 

 

$

 

Change in transaction costs payable

$

511

 

 

$

 

Vesting of early exercised stock options

$

54

 

 

$

11

 

Expiration of Class A common stock redemption right

$

 

 

$

4,500

 

Non-GAAP Financial Measures:

In addition to our financial results determined in accordance with U.S. GAAP, we present Adjusted EBITDA, a non-GAAP financial measure. We use Adjusted EBITDA to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that Adjusted EBITDA, when taken together with the corresponding U.S. GAAP financial measure, provides meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. We consider Adjusted EBITDA to be an important measure because it helps illustrate underlying trends in our business and our historical operating performance on a more consistent basis. We believe that the use of Adjusted EBITDA is helpful to our investors as it is a metric used by management in assessing the health of our business and our operating performance.

However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. A reconciliation is provided below for Adjusted EBITDA to net loss, the most directly comparable financial measure stated in accordance with U.S. GAAP. Investors are encouraged to review net loss and the reconciliation of Adjusted EBITDA to net loss, and not to rely on any single financial measure to evaluate our business.

Adjusted EBITDA is a key performance measure that our management uses to assess our operating performance. Because Adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes. “Adjusted EBITDA” is defined as net loss before depreciation and amortization, provision for income taxes, interest income, interest expense, amortization of debt issuance costs, stock-based compensation, change in fair value of warrant liability, and one-time Merger bonuses and warrant expense.

 

Net Loss to Adjusted EBITDA Reconciliation

(In Thousands, Unaudited)

 

 

Three Months Ended

March 31,

 

2021

 

2020

 

 

 

 

Net loss

$

(51,404)

$

(6,033)

Depreciation and amortization

394

180

Provision for income taxes

90

35

Interest income

(82)

 

(242)

 

Interest expense

10

Amortization of debt issuance costs

144

84

Stock-based compensation

34,230

 

1,404

 

Change in fair value of warrant liability

2,681

 

(71)

 

Merger bonuses

5,219

 

 

Warrant expense in connection with Merger

154

 

 

Adjusted EBITDA

$

(8,574)

$

(4,633)

 

 

Investor Relations

Bob East or Jordan Kohnstam

Westwicke, an ICR company

[email protected]

Media Relations

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: General Health Alternative Medicine Other Health Health Pharmaceutical

MEDIA:

Logo
Logo

Wabtec’s All-Battery Locomotive, FLXdrive, Lowers Freight Train’s Fuel Consumption by More Than 11 Percent in California Pilot

Wabtec’s All-Battery Locomotive, FLXdrive, Lowers Freight Train’s Fuel Consumption by More Than 11 Percent in California Pilot

  • FLXdrive is the world’s first 100% battery-powered, heavy-haul freight locomotive
  • On a mission to net-zero emissions, the FLXdrive battery locomotive uses 18,000 batteries to cut the world’s carbon footprint

PITTSBURGH–(BUSINESS WIRE)–
Wabtec Corporation (NYSE: WAB) announced today a rail industry first as its FLXdrive battery-electric locomotive delivered more than an 11-percent average reduction in fuel consumption and greenhouse gas emissions for an entire train. It is the equivalent of over 6,200 gallons of diesel fuel saved and approximately 69 tons of CO2 emissions reduced.

These outcomes are the result of a three-month pilot with BNSF Railway, the largest railroad in the U.S., where the FLXdrive, the world’s first 100-percent battery locomotive, was put to the test in revenue service across more than 13,320 miles of hilly terrain in San Joaquin Valley, California – a territory surrounded by mountains. The region is classified as a non-attainment area, where the air quality is worse than the National Ambient Air Quality Standards.

“The FLXdrive battery-electric locomotive is a defining moment for freight rail and will accelerate the industry toward low- to zero-emission locomotives,” said Eric Gebhardt, Wabtec Chief Technology Officer. “It builds upon the rail industry’s position as the most efficient and sustainable mode of transportation. Building on our long history of pioneering train energy management technologies, this demonstration of coupling 2.4 megawatt hours of battery storage into the mix fully validated our assumptions for the potential for this next generation technology to further drive efficiencies and greenhouse gas reductions. At more than 6 megawatt hours, Wabtec’s next version of FLXdrive technology will have an opportunity to reduce fuel consumption and emissions by up to 30 percent – putting the industry on the cusp of a once-in-a-generation improvement in energy savings and emission reductions.”

The California pilot program was part of a $22.6 million grant from the California Air Resource Board awarded to Wabtec, BNSF and the San Joaquin Valley Air Pollution Control District. The 430,000-pound FLXdrive in the pilot boasts 18,000 lithium-ion battery cells. The battery locomotive charged at the rail yard and recharged during the trip through regenerative braking. The FLXdrive manages the overall train energy flow and distribution through its Trip Optimizer system, an intelligent cruise control system programmed through artificial intelligence to respond to every twist and grade of the track in the most energy-efficient way possible.

Wabtec’s next step is to build a second-generation locomotive with a battery capacity of more than 6 megawatt hours – a level of energy that can reduce a locomotive consist’s fuel consumption and carbon emissions by up to 30 percent, even while hauling several thousand tons of freight in a mile-long train. A fleet of second-generation FLXdrives will be commercialized and could enter supply chain routes in the next few years.

Wabtec’s goal is to develop the next generation of zero-emission locomotives. The company has a clear path to power new locomotives – and repower existing locomotives – with batteries, hydrogen internal combustion engines, and hydrogen fuel cells. It is part of Wabtec’s vision for the rail industry to play a key role in building a clean energy economy and reduce carbon emissions globally by up to 300 tons per year.

About Wabtec Corporation

Wabtec Corporation is a leading global provider of equipment, systems, digital solutions and value-added services for freight and transit rail. Drawing on nearly four centuries of collective experience across Wabtec, GE Transportation and Faiveley Transport, the company has unmatched digital expertise, technological innovation, and world-class manufacturing and services, enabling the digital-rail-and-transit ecosystems. Wabtec is focused on performance that drives progress, creating transportation solutions that move and improve the world. The freight portfolio features a comprehensive line of locomotives, software applications and a broad selection of mission-critical controls systems, including Positive Train Control (PTC). The transit portfolio provides highly engineered systems and services to virtually every major rail transit system around the world, supplying an integrated series of components for buses and all train-related market segments that deliver safety, efficiency and passenger comfort. Along with its industry-leading portfolio of products and solutions for the rail and transit industries, Wabtec is a leader in mining, marine, and industrial solutions. Based in Pittsburgh. Visit: www.WabtecCorp.com

Media Contacts:

Tim Bader

682-319-7925

[email protected]

KEYWORDS: United States North America California Pennsylvania

INDUSTRY KEYWORDS: Other Transport Environment Technology Rail Transport Alternative Energy Software Energy Logistics/Supply Chain Management

MEDIA:

Logo
Logo